Checkpoint Inhibitors in Malignant Pleural Mesothelioma
0 Pogledi
• 07/02/23
0
0
Ugraditi
administrator
Pretplatnici
Mark Socinski, MD; Mary Jo Fidler, MD; Roy Herbst, MD, PhD; Geoffrey Oxnard, MD; and Naiyer Rizvi, MD discuss the potential for checkpoint inhibitors, such as pembrolizumab, for malignant mesothelioma. Also discussed is the importance of trials that can be done in the community setting.
Prikaži više
Komentari na Facebooku
SORT BY-
Najbolji komentari
-
Najnoviji komentari